Diversified Trust Co Has $2.16 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Diversified Trust Co lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 29,504 shares of the biopharmaceutical company’s stock after selling 3,201 shares during the period. Diversified Trust Co’s holdings in Gilead Sciences were worth $2,161,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Tompkins Financial Corp boosted its position in Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the period. Fortitude Family Office LLC acquired a new position in Gilead Sciences in the 4th quarter valued at $29,000. Private Wealth Management Group LLC acquired a new position in Gilead Sciences in the 4th quarter valued at $29,000. Sachetta LLC bought a new position in Gilead Sciences in the 4th quarter worth $30,000. Finally, Rakuten Securities Inc. acquired a new position in Gilead Sciences during the 4th quarter worth $33,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.29% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on GILD. Oppenheimer reiterated an “outperform” rating and issued a $105.00 price objective on shares of Gilead Sciences in a research note on Friday, April 19th. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Morgan Stanley lowered their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price for the company in a research note on Wednesday, April 24th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. Twelve research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $83.47.

Gilead Sciences Stock Up 0.0 %

Shares of NASDAQ GILD opened at $68.64 on Tuesday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08. The business has a fifty day moving average of $65.98 and a two-hundred day moving average of $72.51. The stock has a market cap of $85.52 billion, a PE ratio of 190.67, a PEG ratio of 2.92 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period last year, the firm posted $1.37 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.49%. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.